40000-79-1

Basic information

• Product Name: 3,4-Dihydro-1,8-naphthyridin-2(1H)-one
• Synonyms: 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDIN-2-ONE;3,4-Dihydro-1,8-naphthyridin-2(1H)-one;3,4-dihydro-1H-[1,8]napht...;1,8-Naphthyridin-2(1H)-one, 3,4-dihydro;2-Oxo-1,2,3,4-tetrahydro-1,8-naphthyridine;1,2,3,4-tetrahydro-1,8-naphthyridin-2-one
• CAS NO: 40000-79-1
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16
• Mol File: 40000-79-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 301 ºC
• Flash Point: 136 ºC
• Appearance: /
• Density: 1.33
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.569
• PKA: 4.13±0.20(Predicted)
• CAS DataBase Reference: 3,4-Dihydro-1,8-naphthyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-1,8-naphthyridin-2(1H)-one(40000-79-1)
• EPA Substance Registry System: 3,4-Dihydro-1,8-naphthyridin-2(1H)-one(40000-79-1)

Safety Data

• Hazardous Substances Data: 40000-79-1(Hazardous Substances Data)

Usage

General Description

3,4-Dihydro-1,8-naphthyridin-2(1H)-one, also known as DHN, is a chemical compound belonging to the class of naphthyridine derivatives. It is a heterocyclic compound with a fused ring structure containing a nitrogen atom. DHN has been studied for its pharmaceutical properties and has been found to exhibit analgesic and anti-inflammatory effects. It has also been investigated for its potential use in the treatment of neurological disorders and as an anti-cancer agent. DHN can be synthesized through various chemical reactions and has shown promise in preclinical studies for its pharmacological applications. However, further research is needed to fully understand its potential uses and mechanisms of action.

InChI:InChI=1/C8H8N2O/c11-7-4-3-6-2-1-5-9-8(6)10-7/h1-2,5H,3-4H2,(H,9,10,11)

Upstream product

• 15936-09-1 1,8-naphthyridine-2(1H)-one 
• 844503-09-9 3-ethenyl-2-nitropyridine 
• 201230-82-2 carbon monoxide 
• 1417626-90-4 C₁₀H₁₀N₂O₃ 
• 23612-60-4 2-amino-3-(bromomethyl)pyridine hydrobromide 

Downstream Products

• 1417626-72-2 1-(4-cyclohexylpiperazin-1-yl)-4-[2(1H)-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]butan-1-one 
• 1417626-73-3 1-(4-cyclohexylpiperazin-1-yl)-5-[2(1H)-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]pentan-1-one 

Relevant articles and documents

Dehydrogenative and Redox-Neutral N-Heterocyclization of Aminoalcohols Catalyzed by Manganese Pincer Complexes

A new manganese catalyzed heterocyclization of aminoalcohols has been accomplished. A wide range of heterocycles were synthesized, including 1,2,3,4-tetrahydroquinolines, dihydroquinolinones, and 2,3,4,5-tetrahydro-1H-benzo[b]azepines. The reaction is performed under mild reaction conditions using air and moisture stable manganese catalysts. The desired heterocycles were obtained in good to excellent yields.

2-Aminopyridine Derivatives as Potential σ2 Receptor Antagonists

σ2 Receptor research is receiving increasing interest with regard to the potential of σ2 proteins as targets for tumor therapy and diagnosis. Nevertheless, knowledge about the σ2 receptor is far from conclusive. The paucity and modest affinity of known σ2 antagonists represent one of the limitations to σ2 receptor research. Previous studies of the high-affinity σ2 agonist 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-n-propyl]piperazine 4 (PB28) suggested that a decrease in lipophilicity might lead to σ2 ligands devoid of antiproliferative activity (potential σ2 antagonists). With the aim of producing σ2 receptor antagonists, we replaced the tetralin nucleus of compound 4 with a 2-aminopyridine moiety. A series of compounds with high affinity for both σ subtypes and with no antiproliferative activity in various cells (mouse HT-22, human SK-N-SH, MCF-7wt, and MCF-7σ1) were obtained. The effect on Ca2+ mobilization was investigated for high-affinity compounds 18 and 4, which showed opposite effects. All of the data support the new 2-aminopyridines as high-affinity σ ligands with σ2 antagonist and σ1 agonist activity, and, despite the lack of significant σ2 versus σ1 selectivity, these novel compounds may be better tools for σ receptor research than the known low-affinity σ2 antagonists.